Ningbo Menovo Pharmaceutical Co., Ltd.
Symbol: 603538.SS
SHH
14.81
CNYMarket price today
-164.8178
P/E Ratio
-1.2361
PEG Ratio
3.14B
MRK Cap
- 0.01%
DIV Yield
Ningbo Menovo Pharmaceutical Co., Ltd. (603538-SS) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3108.99 | 724.7 | 1009.3 | 793.2 | |||||||||||||
balance-sheet.row.short-term-investments | 961.42 | 268.6 | 217.4 | 371.4 | |||||||||||||
balance-sheet.row.net-receivables | 1197.96 | 320.7 | 231.5 | 266.2 | |||||||||||||
balance-sheet.row.inventory | 2630.14 | 612.6 | 594.4 | 579.7 | |||||||||||||
balance-sheet.row.other-current-assets | 198.07 | 50.3 | 59.2 | 63.4 | |||||||||||||
balance-sheet.row.total-current-assets | 7254.8 | 1759.4 | 1894.4 | 1702.4 | |||||||||||||
balance-sheet.row.property-plant-equipment-net | 7582.87 | 1900.3 | 1801.9 | 1614.7 | |||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 22.7 | |||||||||||||
balance-sheet.row.intangible-assets | 802.34 | 206.2 | 172.5 | 201.7 | |||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 802.34 | 206.2 | 172.5 | 224.4 | |||||||||||||
balance-sheet.row.long-term-investments | 832.39 | 315.3 | 82.7 | -51.8 | |||||||||||||
balance-sheet.row.tax-assets | 335.17 | 42.7 | 123.1 | 33.3 | |||||||||||||
balance-sheet.row.other-non-current-assets | 942.78 | 199.6 | 344.8 | 478.5 | |||||||||||||
balance-sheet.row.total-non-current-assets | 10495.55 | 2664.1 | 2525.1 | 2299.1 | |||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.total-assets | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.account-payables | 2040.98 | 553.7 | 499.3 | 389.1 | |||||||||||||
balance-sheet.row.short-term-debt | 2165.58 | 542.8 | 497 | 505 | |||||||||||||
balance-sheet.row.tax-payables | 115.34 | 25.5 | 72.1 | 34.6 | |||||||||||||
balance-sheet.row.long-term-debt-total | 3022.3 | 759.6 | 705.6 | 755.3 | |||||||||||||
Deferred Revenue Non Current | 330.02 | 81.5 | 70.6 | 48.7 | |||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 220.86 | - | - | - | |||||||||||||
balance-sheet.row.other-current-liab | 8.2 | 2 | 171 | 3.9 | |||||||||||||
balance-sheet.row.total-non-current-liabilities | 3592.57 | 859.6 | 884 | 876.2 | |||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||
balance-sheet.row.capital-lease-obligations | 102.15 | 15.7 | 30.3 | 28 | |||||||||||||
balance-sheet.row.total-liab | 8956.27 | 2237.8 | 2246.2 | 2023 | |||||||||||||
balance-sheet.row.preferred-stock | 72.59 | 36.3 | 0 | 0 | |||||||||||||
balance-sheet.row.common-stock | 853.57 | 213.4 | 213.4 | 151.3 | |||||||||||||
balance-sheet.row.retained-earnings | 4918.84 | 1210.6 | 1234.3 | 937.4 | |||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 986.88 | 75.6 | 101.4 | 77.6 | |||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1595.49 | 560.4 | 535.9 | 585.2 | |||||||||||||
balance-sheet.row.total-stockholders-equity | 8427.36 | 2096.3 | 2085 | 1751.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 17750.35 | 4423.5 | 4419.5 | 4001.5 | |||||||||||||
balance-sheet.row.minority-interest | 366.72 | 89.4 | 88.3 | 227 | |||||||||||||
balance-sheet.row.total-equity | 8794.08 | 2185.7 | 2173.2 | 1978.5 | |||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 17750.35 | - | - | - | |||||||||||||
Total Investments | 1259.87 | 315.3 | 300.1 | 319.6 | |||||||||||||
balance-sheet.row.total-debt | 5187.88 | 1302.5 | 1202.6 | 1260.4 | |||||||||||||
balance-sheet.row.net-debt | 3040.31 | 846.4 | 410.7 | 838.6 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -17.82 | 367.6 | 158.1 | 173.1 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 90.3 | 101.8 | 98.9 | 85 | ||||||||||||
cash-flows.row.deferred-income-tax | -13.64 | -40.2 | -21 | 18.4 | ||||||||||||
cash-flows.row.stock-based-compensation | 11.27 | 24.7 | 5.3 | 10.9 | ||||||||||||
cash-flows.row.change-in-working-capital | -124.06 | -85.4 | -62.2 | -2.8 | ||||||||||||
cash-flows.row.account-receivables | -98.84 | -213.6 | -50.9 | -28.2 | ||||||||||||
cash-flows.row.inventory | -49.56 | -183 | -124.7 | -83 | ||||||||||||
cash-flows.row.account-payables | 0 | 351.4 | 134.4 | 63.3 | ||||||||||||
cash-flows.row.other-working-capital | 24.33 | -40.2 | -21 | 45.1 | ||||||||||||
cash-flows.row.other-non-cash-items | 36.58 | -91.4 | 41.5 | -32.9 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -28.65 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.acquisitions-net | 0.3 | 487.9 | -47.1 | 0.5 | ||||||||||||
cash-flows.row.purchases-of-investments | -994.74 | -713.9 | -1640.5 | -865 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 853.67 | 902.5 | 1562.2 | 693.5 | ||||||||||||
cash-flows.row.other-investing-activites | -116.67 | -54.6 | 52 | 3.8 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -247.84 | 50.3 | -603.3 | -479 | ||||||||||||
cash-flows.row.debt-repayment | -399.52 | -749.5 | -788.1 | -802.5 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0.1 | 0.2 | 0.5 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | -0.1 | -0.2 | -0.5 | ||||||||||||
cash-flows.row.dividends-paid | -60.49 | -50 | -13.8 | -41 | ||||||||||||
cash-flows.row.other-financing-activites | 446.21 | 621.1 | 1385.1 | 981.9 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 60.68 | -178.5 | 583.1 | 138.4 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -22.05 | 14.6 | -2.3 | -2 | ||||||||||||
cash-flows.row.net-change-in-cash | -237.86 | 163.4 | 198.2 | -91 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 1234.49 | 537 | 373.6 | 174.5 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 1472.34 | 373.6 | 175.4 | 265.5 | ||||||||||||
cash-flows.row.operating-cash-flow | -28.65 | 277 | 220.6 | 251.6 | ||||||||||||
cash-flows.row.capital-expenditure | -142.43 | -571.6 | -529.9 | -311.7 | ||||||||||||
cash-flows.row.free-cash-flow | -171.08 | -294.7 | -309.3 | -60.1 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 1232.95 | 1216.5 | 1457 | 1258.1 | |||||||||||||
income-statement-row.row.cost-of-revenue | 839.39 | 840.9 | 872.8 | 788.9 | |||||||||||||
income-statement-row.row.gross-profit | 393.56 | 375.6 | 584.2 | 469.2 | |||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||
income-statement-row.row.research-development | 99.54 | - | - | - | |||||||||||||
income-statement-row.row.selling-general-administrative | 57.01 | - | - | - | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.other-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.operating-expenses | 305.9 | 291.2 | 341.4 | 281 | |||||||||||||
income-statement-row.row.cost-and-expenses | 1145.29 | 1132.1 | 1214.2 | 1069.9 | |||||||||||||
income-statement-row.row.interest-income | 6.12 | 5.5 | 5.7 | 2.2 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 52.13 | - | - | - | |||||||||||||
income-statement-row.row.total-other-income-expensenet | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||
income-statement-row.row.other-operating-expenses | -11.95 | -10.8 | 116.4 | 110.8 | |||||||||||||
income-statement-row.row.total-operating-expenses | -77.38 | -76.4 | -21.2 | -7.6 | |||||||||||||
income-statement-row.row.interest-expense | 30.96 | 29.1 | 27.4 | 27.2 | |||||||||||||
income-statement-row.row.depreciation-and-amortization | 125.92 | 118.5 | 128.3 | 124.1 | |||||||||||||
income-statement-row.row.ebitda-caps | 59.17 | - | - | - | |||||||||||||
income-statement-row.row.operating-income | -15.63 | 18.7 | 405.3 | 187.9 | |||||||||||||
income-statement-row.row.income-before-tax | -27.57 | 8 | 384.2 | 180.3 | |||||||||||||
income-statement-row.row.income-tax-expense | -13.31 | -8.2 | 16.5 | 22.2 | |||||||||||||
income-statement-row.row.net-income | -17.82 | 11.6 | 338.9 | 142.5 |
Frequently Asked Question
What is Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) total assets?
Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) total assets is 4423515920.000.
What is enterprise annual revenue?
The annual revenue is 550731997.000.
What is firm profit margin?
Firm profit margin is 0.319.
What is company free cash flow?
The free cash flow is -0.853.
What is enterprise net profit margin?
The net profit margin is -0.014.
What is firm total revenue?
The total revenue is -0.013.
What is Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) net profit (net income)?
The net profit (net income) is 11585592.000.
What is firm total debt?
The total debt is 1302458461.000.
What is operating expences number?
The operating expences are 291175048.000.
What is company cash figure?
Enretprise cash is 351891745.000.